Markers and Immunoprofile of Ewing’s Sarcoma/Primitive Neuroectodermal Tumors (PNETs)

[1]  M. Beckerle,et al.  EWS/FLI utilizes NKX2-2 to repress mesenchymal features of Ewing sarcoma , 2015, Genes & cancer.

[2]  T. Kasai,et al.  The combination of CD99 and NKX2.2, a transcriptional target of EWSR1-FLI1, is highly specific for the diagnosis of Ewing sarcoma , 2014, Virchows Archiv.

[3]  H. Tsuda,et al.  NKX2.2 is a Useful Immunohistochemical Marker for Ewing Sarcoma , 2012, The American journal of surgical pathology.

[4]  J. Teruya-Feldstein,et al.  Immunohistochemical Evaluation of FLI-1 in Acute Lymphoblastic Lymphoma (ALL): A Potential Diagnostic Pitfall , 2009, Applied immunohistochemistry & molecular morphology : AIMM.

[5]  V. A. Flørenes,et al.  Fli-1 expression in malignant melanoma. , 2008, Histology and histopathology.

[6]  E. Lalli,et al.  DAX1, a direct target of EWS/FLI1 oncoprotein, is a principal regulator of cell-cycle progression in Ewing's tumor cells , 2008, Oncogene.

[7]  S. Yohe,et al.  Application of immunohistochemistry to soft tissue neoplasms. , 2008, Archives of pathology & laboratory medicine.

[8]  O. Delattre,et al.  The orphan nuclear receptor DAX1 is up‐regulated by the EWS/FLI1 oncoprotein and is highly expressed in Ewing tumors , 2006, International journal of cancer.

[9]  A. D. Tos,et al.  Utility of the immunohistochemical detection of FLI-1 expression in round cell and vascular neoplasm using a monoclonal antibody , 2004, Modern Pathology.

[10]  A. Folpe,et al.  Immunohistochemical Detection of FLI-1 Protein Expression: A Study of 132 Round Cell Tumors With Emphasis on CD99-Positive Mimics of Ewing's Sarcoma/Primitive Neuroectodermal Tumor , 2000, The American journal of surgical pathology.